ImmunityBio (IBRX) Stock Surges 12% Following Major Hedge Fund Endorsement

Key Takeaways

• Shares of ImmunityBio (IBRX) climbed more than 12% to finish at $8.83 on September 29, 2026.
• GA-Courtenay Special Situations Fund featured ImmunityBio as a key position in its second-quarter 2026 investor update.
• The investment firm estimates Anktiva could address an annual market exceeding $5.8 billion, potentially expanding beyond $43 billion with US lung cancer clearance.
• The company announced a distribution agreement with Accord Healthcare covering 30 international markets.
• ImmunityBio launched a Phase 1b clinical study evaluating N-803 alongside two additional oncology agents in bladder cancer.

ImmunityBio (IBRX) shares finished trading at $8.83 on September 29, 2026, marking a single-day increase exceeding 12%. The biotechnology company has posted gains of more than 11% over the trailing month and has surged over 256% across the past twelve months.

ImmunityBio, Inc., IBRX

This significant performance has attracted attention from specialized investment funds seeking opportunities in the biotechnology sector. Green Ash Partners’ GA-Courtenay Special Situations Fund identified ImmunityBio as a notable position in its second-quarter 2026 shareholder communication.

The fund’s investment rationale centers on ImmunityBio’s production infrastructure. The organization maintains annual manufacturing capability for one million vials of Anktiva, its primary commercial product, which carries a list price of $35,000 per dose.

Using this production volume, the fund calculates a total addressable market exceeding $5.8 billion annually based solely on existing regulatory approvals. The analysis also highlighted a 99% trailing gross profit margin for the medication.

Expansion Scenarios Beyond Current Approvals

The fund’s market projections extend well beyond the $5.8 billion baseline. Anktiva has received authorization for lung cancer treatment in markets outside the United States, and the fund anticipates potential US regulatory clearance by 2028.

Should this approval materialize, the fund projects the total addressable opportunity could surpass $43 billion annually. This projection incorporates conservative pricing assumptions across all indications.

ImmunityBio has simultaneously pursued strategic commercial partnerships. The firm established a collaboration with Accord Healthcare to broaden Anktiva availability throughout 30 territories, encompassing the United Kingdom, European Union member states, Norway, Iceland, and Liechtenstein.

Accord will deploy over 100 professionals across sales, medical affairs, and marketing functions to support the launch. ImmunityBio has additionally established an Irish operating entity in Dublin to facilitate European distribution operations.

Company founder Patrick Soon-Shiong stated the strategy focuses on expanding Anktiva access through completion of a randomized clinical study in BCG-naïve patients. This patient population includes individuals with bladder cancer who have not previously received BCG immunotherapy or experienced relapse significantly after prior BCG treatment.

ImmunityBio has also obtained European Union regulatory clearance for Anktiva used alongside BCG. This authorization arrived shortly after Saudi Arabian health authorities encouraged the company to submit an application for its recombinant BCG therapy to address local treatment supply challenges.

Advancing Clinical Development Programs

The company maintains ongoing discussions with Saudi regulators regarding the combination of Anktiva with checkpoint inhibitor medications across various cancer types. In the previous month, Saudi authorities granted accelerated regulatory approval for Anktiva in both metastatic non-small cell lung cancer and BCG-unresponsive bladder cancer.

Regarding clinical development, ImmunityBio has initiated a Phase 1b investigation evaluating N-803 combined with pembrolizumab and enfortumab vedotin. This trial enrolls patients diagnosed with treatment-naïve metastatic urothelial carcinoma, representing an advanced form of bladder cancer.

The protocol employs a single-arm design, where all enrolled participants receive an identical therapeutic regimen. The investigation follows an open-label format, allowing both clinicians and patients full knowledge of administered treatments.

The trial received initial submission on October 14, 2025. The clinical trial registry showed its most recent update on September 21, 2026, suggesting continued progress toward site initiation.

The program remains in preparatory stages and has not yet commenced patient enrollment. Stakeholders can monitor ongoing developments through the ClinicalTrials portal as the study advances.

ImmunityBio maintains a market capitalization of $9.35 billion. The stock has traded within a 52-week range spanning from $1.95 to $12.43.